ERBB2 and endometrial carcinoma: Growdon et al. identified HER2 expression in 59% of endometrial tumors using immunohistochemistry.HER2 gene amplification was evidenced in 18% of tumors; additionally, high expression levels of the variant p95HER2 significantly correlated with high-grade endometrial carcinoma [46].